经肛与腹腔镜全直肠系膜切除术治疗直肠癌的3年无病生存比较:TaLaR随机临床试验
这项在中国16个中心开展的随机、开放标签、非劣效性3期临床试验纳入1115例临床I至III期中低位直肠癌患者,比较经肛全直肠系膜切除术(TME)与腹腔镜TME的3年无病生存。结果显示经肛TME组3年无病生存率为82.1%,腹腔镜TME组为79.4%,差异为2.7%(97.5%CI,-3.0%至8.1%),非劣效性成立。
要点
- 经肛TME组3年无病生存率为82.1%,腹腔镜TME组为79.4%,差异2.7%(97.5%CI,-3.0%至8.1%)。
- 3年无病生存率组间差异的97.5%CI下限高于非劣效界值-10个百分点,非劣效性成立。
- 在中低位直肠癌患者中,经肛TME的3年无病生存不劣于腹腔镜TME。
核心结论
- 在中低位直肠癌患者中,经肛TME的3年无病生存不劣于腹腔镜TME。
研究设计与样本
- 随机、开放标签、非劣效性3期临床试验,在中国16个中心开展。
- 2016年4月至2021年6月共纳入1115例临床I至III期中低位直肠癌患者,末次随访时间为2024年6月。
- 参与者按1:1比例随机分配至经肛TME组(n=558)或腹腔镜TME组(n=557)。
- 主要终点为3年无病生存,非劣效界值为-10%;次要终点包括3年总生存和3年局部复发。
主要发现
- 主要分析集中位年龄为60岁,共纳入692例男性和397例女性患者。
- 经肛TME组3年无病生存率为82.1%(97.5%CI,78.4%-85.8%),腹腔镜TME组为79.4%(97.5%CI,75.6%-83.4%),差异为2.7%(97.5%CI,-3.0%至8.1%)。
- 3年无病生存率组间差异的双侧97.5%CI下限高于非劣效界值-10个百分点。
- 经肛TME组3年局部复发率为3.6%(95%CI,2.0%-5.1%),腹腔镜TME组为4.4%(95%CI,2.6%-6.1%)。
- 经肛TME组3年总生存率为92.6%(95%CI,90.4%-94.8%),腹腔镜TME组为90.7%(95%CI,88.3%-93.2%)。
关键数值与推荐
- 非劣效界值为-10%,用于经肛TME与腹腔镜TME的3年无病生存率比较。
- 3年无病生存率组间差异为2.7%(97.5%CI,-3.0%至8.1%),其97.5%CI下限高于-10个百分点,非劣效性成立。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Previous studies have demonstrated the advantages of short-term histopathological outcomes and complications associated with transanal total mesorectal excision (TME) compared with laparoscopic TME. However, the long-term oncological outcomes of transanal TME remain ambiguous. This study aims to compare 3-year disease-free survival of transanal TME with laparoscopic TME. OBJECTIVE: To evaluate 3-year disease-free survival between transanal TME and laparoscopic TME in patients with rectal cancer. DESIGN, SETTING, AND PARTICIPANTS: This randomized, open-label, noninferiority, phase 3 clinical trial was performed in 16 different centers in China. Between April 2016 and June 2021, a total of 1115 patients with clinical stage I to III mid-low rectal cancer were enrolled. The last date of participant follow-up was in June 2024. INTERVENTIONS: Participants were randomly assigned in a 1:1 ratio before their surgical procedure to undergo either transanal TME (n = 558) or laparoscopic TME (n = 557). MAIN OUTCOMES AND MEASURES: The primary end point was 3-year disease-free survival, with a noninferiority margin of -10% for the comparison between transanal TME and laparoscopic TME. Secondary outcomes included 3-year overall survival and 3-year local recurrence. RESULTS: In the primary analysis set, the median patient age was 60 years. A total of 692 male and 397 female patients were included in the analysis. Three-year disease-free survival was 82.1% (97.5% CI, 78.4%-85.8%) for the transanal TME group and 79.4% (97.5% CI, 75.6%-83.4%) for the laparoscopic TME group, with a difference of 2.7% (97.5% CI, -3.0% to 8.1%). The lower tail of a 2-tailed 97.5% CI for the group difference in 3-year disease-free survival was above the noninferiority margin of -10 percentage points. Furthermore, the 3-year local recurrence was 3.6% (95% CI, 2.0%-5.1%) for transanal TME and 4.4% (95% CI, 2.6%-6.1%) for laparoscopic TME. Three-year overall survival was 92.6% (95% CI, 90.4%-94.8%) for transanal TME and 90.7% (95% CI, 88.3%-93.2%) for laparoscopic TME. CONCLUSIONS AND RELEVANCE: In patients with mid-low rectal cancer, 3-year disease-free survival for transanal TME was noninferior to that of laparoscopic TME. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02966483.
引用
- Zeng Z, Luo S, Zhang H, et al. Transanal vs Laparoscopic Total Mesorectal Excision and 3-Year Disease-Free Survival in Rectal Cancer: The TaLaR Randomized Clinical Trial. JAMA. 2025. PMID: 39847361. doi:10.1001/jama.2024.24276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。